financingSynerkine Pharma BV secures EUR 12.1m in Series A extensionDutch Synerkine Pharma BV has closed a Seris A extension financincg at €12.1m to accelerate clinical development of its pain killer SK-01. more ➔
imagingAI helps classifying brain tumours during surgeryA method to quickly classify central nervous system (CNS) tumours, combining rapid sequencing and deep-learned AI models, may enable molecular diagnosis in less than 90 minutes, Dutch researchers re … more ➔
antibodyAgomab Therapeutics NV raises US$100m in Series C financing Belgian fibrosis specialist Agomab Therapeutics NV has raised US$100m to advance development of its pipeline. more ➔
financingAstronauTx closes £48m Series A financingAlzheimer’s specialist AstronauTx Ltd has closed a £48m Series A financing to create new treatments for Alzheimer’s diseas more ➔
Bioindustra ConsortiumFrench team BioAroma awarded with BISC-E 2023 prizeAt the celebration of the 10th anniversary of the Bio-based Industry Consortium (BIC), the student team BioAroma was presented with the BISC-E 2023 award, which comes with €5000 in prize money. more ➔
Orphan diseasesBreakthrough in microtia treatmentResearchers developed an innovative ear transplant method to treat microtia using tissue-engineered human skin and bioprinted cartilage. more ➔
cell modelsOrakl Oncology SA raises €3m to advance tumour modellingParis-based Orakl Oncology SA has raised €3m to develop its techbio platform for precision oncology. more ➔
SepsisSanofi licences vaccine against bacterial sepsisFrench pharma major Sanofi SA will pay US$175m upfront to Janssen Pharmaceuticals, Inc. for commercialisation of a Phase III vaccine against extraintestinal pathogenic E. coli. more ➔
EventSpain set to unveil the potential of the biologisation of medicine and food productionThe Spanish EU Council Presidency is to set the course for the internationally competitive use of biotechnology in drug development, plant breeding and food production. more ➔
financingMogrify Ltd extends Series A financing to $46mBritish in-vivo cell programming specialist Mogrify Ltd has added US$10m to its US$36m Series A financing. more ➔
